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ABSTRACT
Background. Management and outcomes of patients with
recurrent intrahepatic cholangiocarcinoma (ICC) following
curative-intent surgery are not well documented. We
sought to characterize the treatment of patients with
recurrent ICC and define therapy-specific outcomes.
Methods. Patients who underwent surgery for ICC from
1990 to 2013 were identified from an international data-
base. Data on clinicopathological characteristics, operative
details, recurrence, and recurrence-related management
were recorded and analyzed.
Results. A total of 563 patients undergoing curative-intent
hepatic resection for ICC who met the inclusion criteria were
identified. With a median follow-up of 19 months, 400
(71.0 %) patients developed a recurrence. At initial surgery,
treatment was resection only (98.8 %) or resection ? ablation
(1.2 %). Overall 5-year survival was 23.6 %; 400 (71.0 %)
patients recurred with a median disease-free survival of 11.2
months. First recurrence site was intrahepatic only (59.8 %),
extrahepatic only (14.5 %), or intra- and extrahepatic (25.7 %).
Overall, 210 (52.5 %) patients received best supportive care
(BSC), whereas 190 (47.5 %) patients received treatment, such
as systemic chemotherapy-only (24.2 %) or repeat liver-di-
rected therapy ± systemic chemotherapy (75.8 %). Repeat
liver-directed therapy consisted of repeat hepatic resection ±
ablation (28.5 %), ablation alone (18.7 %), and intra-arterial
therapy (IAT) (52.8 %). Among patients who recurred, median
survival from the time of the recurrence was 11.1 months (BSC
8.0 months, systemic chemotherapy-only 16.8 months, liver-
directed therapy 18.0 months). The median survival of patients
undergoing resection of recurrent ICC was 26.7 months versus
9.6 months for patients who had IAT (p\0.001).
Conclusions. Recurrence following resection of ICC was
common, occurring in up to two-thirds of patients. When
there is recurrence, prognosis is poor. Only 9 % of patients
underwent repeat liver resection after recurrence, which
offered a modest survival benefit.
Intrahepatic cholangiocarcinoma (ICC) is an aggressive
neoplasm arising from the epithelial cells of the intrahep-
atic bile ducts. ICC accounts for 10–15 % of all primary
liver cancers and is the second most common primary liver
tumor after hepatocellular carcinoma.1,2 The incidence of
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ICC has increased in the past 30 years from 0.32 per
100,000 to 0.85 per 100,000 worldwide and similarly from
0.13 per 100,000 to 0.67 per 100,000 in the United
States.3,4 Mortality associated with ICC also has increased
over time from 0.7 per 1,000,000 in the 1970s to 6.9 per
1,000,000 in 2000, paralleling the increase in the incidence
of ICC.4
Many patients with ICC present with advanced disease,
characterized by large tumor size, vascular invasion, and
multifocality.5 As such, only 20–40 % of patients with ICC
are considered potentially operable at the time of presen-
tation and are offered surgical resection.6,7 When feasible,
hepatic resection remains the best potential curative treat-
ment for ICC. However, even after curative-intent surgery,
the 5-year survival of patients undergoing liver resection
ranges from only 30–35 %, with a median overall survival
of approximately 28 months.5 The addition of adjuvant
chemotherapy and/or radiotherapy with surgery has simi-
larly failed to offer a durable survival benefit for the
majority of patients; less than one-third of these patients
survive beyond 5 years.5,8,9
Data for risk factors associated with recurrence, as well
as data characterizing the treatment and outcome of
patients with recurrent ICC are lacking. Specifically, few
studies have evaluated the rates and patterns of recurrence
after hepatic resection for ICC. Most of these studies did
not report the management of recurrence, nor did these
studies define the therapy-specific outcomes for recurrent
disease.10–15 Furthermore, most of these studies suffered
from a sample size and were based on single-institution
experience.11,12,16
During the past decade, there has been increasing
interest in the surgical management of recurrent hepato-
biliary malignancies. Several studies have demonstrated
the efficacy of repeat surgical resection or ablation for the
treatment of colorectal liver metastasis and hepatocellular
carcinoma; however, there is a paucity of data on the
management of recurrent ICC.16–18 Given this, the objec-
tive of the current study was to characterize the treatment
of patients with recurrent ICC and define therapy-specific
outcomes. Specifically, using a large multi-institutional
cohort of patients, we sought to determine the rate and the
pattern of recurrent disease following curative-intent sur-
gery for ICC, as well as define the therapy-specific
outcome of patients treated for recurrent disease.
MATERIALS AND METHODS
Patient Demographic and Clinical Data
Patients undergoing curative-intent hepatic resection for
ICC between 1990 and 2013 at 1 of 12 major hepatobiliary
centers in the United States, Europe, Australia, and Asia
(Johns Hopkins Hospital, Baltimore, MD; Medical College
of Wisconsin, Milwaukee, WI; Stanford University, Stan-
ford, CA; University of Virginia, Charlottesville, VA;
Emory University, Atlanta, GA; University of Pittsburgh,
Pittsburgh, PA; Fundeni Clinical Institute of Digestive
Disease, Bucharest, Romania; Curry Cabral Hospital, Lis-
bon, Portugal; Hopitaux Universitaires De Geneve,
Geneve, Switzerland; Ospedale San Raffaele, Milan, Italy;
Royal Prince Alfred Hospital, University of Sydney, Syd-
ney, Australia; Eastern Hepatobiliary Surgery Hospital,
Shanghai, China) were identified. Only patients with his-
tologically confirmed ICC were included in the study
group. Patients who underwent a palliative operation, had
metastatic disease, or experienced perioperative mortality
within 30 days of surgery were excluded from analysis.
Patients who underwent only ablation or intra-arterial
therapy (IAT) as treatment of the primary tumor were also
excluded. The Institutional Review Board of each institu-
tion approved the study.
Standard patient demographic and clinicopathologic
data were collected, including age, sex, presence of cir-
rhosis, and tumor-specific characteristics. In particular,
data were collected on primary tumor size, number, grade,
lymph node status, and presence of vascular invasion
(macroscopic and microscopic), perineural invasion, biliary
invasion, and direct invasion of contiguous organs. Data on
tumor stage were also collected according to 7th edition
AJCC staging system.19 Resection margin status was
recorded and classified as microscopically negative (R0),
microscopically positive (R1), or macroscopically positive
(R2). Data regarding treatment details of the primary tumor
also were collected, including type of surgery and receipt
of adjuvant chemotherapy and radiotherapy. Perioperative
complications and mortality were considered within 90
days from the operation.20 Complications were categorized
based on the Clavien-Dindo classification system, with
minor complications defined as grade I or II and major
complications as grade III or IV.21
Date of last follow-up, vital status, and recurrence-related
information were collected on all patients. Recurrence was
defined as the presence of a biopsy-proven tumor or an image
that was highly suspicious of tumor recurrence. In general,
similar to previous studies, patients had surveillance imaging
every 3–4 months for the first 1–3 years and every 6 months
from 3 to 5 years.22–24 Information regarding the location
and number of lesions, as well as the disease-free interval
from the date of initial operation to the development of
recurrent disease was recorded. For the cohort of patients
who developed repeat recurrences, data on the pattern and
time interval between subsequent recurrences also were
noted. Recurrences were classified as intrahepatic or extra-
hepatic, and the specific site of recurrence was recorded
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(lung, adrenal, bone, peritoneum, etc.) when available. Data
on treatment of recurrent ICC also were collected and for the
purpose of the study were classified as best supportive care
(BSC), liver-directed therapy, and chemotherapy-only.
Liver-directed therapy was considered as hepatic resection±
ablation, ablation only, and IAT; selection of patients for
liver-directed therapy was at the discretion of the treating
surgeon.
Statistical Analysis
Discrete variables were described as medians with
interquartile range (IQR) and categorical variables were
described as totals and frequencies. Univariate comparisons
were assessed using the chi-squared test or Fisher’s exact test
as appropriate. Univariate and multivariate logistic regres-
sion models were assessed to determine factors associated
with ‘‘any site’’ recurrence and site-specific recurrence.
Variables with univariate significance (P \ 0.05) were
entered into the multivariate model. Overall survival (OS)
for the study population and recurrence-free survival (RFS)
were estimated using the Kaplan–Meier method, and the
differences in OS and RFS were assessed with the log-rank
test. All analyses were performed with STATA version 12.0
(StataCorp, College Station, TX), and P\0.05 (two-tailed)
was considered statistically significant.
RESULTS
Clinicopathological and Treatment Characteristics
A total of 563 patients undergoing curative-intent hepatic
resection for ICC who met the inclusion criteria were iden-
tified. With a median follow-up of 19 months, 400 (71.0 %)
patients developed a recurrence. Baseline characteristics of
the population that recurred after curative-intent therapy for
ICC are summarized in Supplementary Table 1. The median
patient age was 59 years (IQR 49–69); the majority of
patients were male (n= 213, 53.4 %) and non-Hispanic white
(n = 296, 78.3 %). A minority of patients had cirrhosis of the
background liver (n = 47, 11.8 %). The median size of the
largest tumor was 7 cm (IQR 5.0–9.5 cm). One third of
tumors were solitary (n = 137, 34.9 %), and the median
tumor burden was 1 (IQR 1–2). At the time of surgery, the
majority of patients underwent a hemihepatectomy (n = 175,
44.1 %). The remaining patients underwent either less than a
hemihepatectomy (n = 126; 31.7 %) or extended hemi-
hepatectomy (n = 96; 24.2 %). Only 5 (1.2 %) patients
underwent a concomitant liver ablation plus resection.
Complete R0 resection was achieved in the majority of
patients (n = 328, 82.4 %). On the final pathological evalu-
ation, almost one-quarter of patients presented with vascular
invasion (microvascular invasion: n = 82, 20.5 %;
macrovascular invasion: n = 19, 4.8 %; both: n = 33, 8.2 %).
Biliary invasion (n = 59, 14.8 %) and direct invasion of
contiguous organs (n = 43, 10.8 %) were less common. The
majority of patients had a mass-forming ICC (n = 280,
80.4 %) and a moderately differentiated (n = 241, 61.6 %) or
poorly differentiated/undifferentiated tumor (n = 107,
27.4 %). Less than one-quarter of patients was found to have
lymph node metastasis (n = 74, 18.5 %). Among those
patients who experienced recurrence and had information on
AJCC stage, the majority was either stage I (n = 81, 32.4 %)
or stage IVa (n = 86, 34.4 %). A total of 176 (44.0 %)
patients experienced a postoperative complication. Among
these patients, 106 (59.9 %) had a minor complication,
whereas 71 (40.1 %) had a major complication. Half of
patients received adjuvant chemotherapy (n = 201, 50.2 %),
whereas only a small subset (n = 44, 11.0 %) received
adjuvant radiotherapy.
Patterns and Predictors of Recurrence
Among the 400 patients who experienced a recurrence,
239 (59.8 %) developed only intrahepatic disease, whereas
a minority (n = 58, 14.5 %) had only extrahepatic disease
and 103 (25.7 %) had both intra- and extrahepatic disease.
The most common site of extrahepatic recurrence was lung
(29.8 %), followed by distant lymph nodes (23.6 %), and
peritoneum (21.1 %; Table 1).
Median, 1-, 3-, and 5-year RFS was 11.2 months, 47.8,
22.4, and 17.4 % respectively. The median RFS was
independent from the pattern of recurrence (intrahepatic
only: 7.4 months vs. extrahepatic only: 8.9 months, P =
0.33). Among patients who experienced a recurrence, vir-
tually all recurrences occurred within 5 years, with the
highest risk being within the first 2 years of surgery
(Fig. 1). Several patient and tumor-related factors were
associated with ‘‘any site’’ recurrence, including presence
TABLE 1 Patterns of recurrence following curative-intent surgery
of intrahepatic cholangiocarcinoma
Characteristic Recurrence (n = 400)
Intrahepatic only 239 (59.8)
Extrahepatic only 58 (14.5)
Intrahepatic and extrahepatic 103 (25.7)





Lymph node 38 (23.6)
Other 21 (13.0)
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of cirrhosis in the background liver, tumor size and num-
ber, vascular invasion, tumor grade, as well as lymph node
status (Table 2). Specifically, patients who experienced a
recurrence were more likely to have cirrhosis (hazard ratio
[HR] 1.62, 95 % confidence interval [CI] 1.17–2.25; P =
0.004), multiple lesions (HR 1.43, 95 % CI 1.15–1.78; P =
0.001), and large tumors (HR 1.38, 95 % CI 1.11–1.70; P =
0.003). Evidence of microvascular invasion (HR 1.56,
95 % CI 1.21–2.02; P = 0.001) and macrovascular invasion
(HR 1.60, 95 % CI 1.06–2.42; P=0.025) were each asso-
ciated with a higher risk of ‘‘any site’’ recurrence. In
addition, the presence of lymph node metastasis (HR 1.46,
95 % CI 1.08–1.97; P\ 0.001) and poor differentiation
(HR 1.30, 95 % CI 1.03–1.64; P = 0.024) similarly
increased the risk of recurrence. Patients with periductal-
infiltrating tumor (HR 1.70, 95 % CI 1.05–2.76; P = 0.032)
and those with mass-forming morphology ± periductal-
infiltrating aspects (HR 1.74, 95 % CI 1.16–2.63; P =
0.008) also were more likely to experience recurrence.
In examining the pattern of recurrence, several factors
were associated with the specific patterns of recurrence
(Table 2). For example, patients with cirrhosis were at
increased risk of intrahepatic recurrence (HR 1.91, 95 %
CI 1.31–2.80; P = 0.001). Similarly multiple lesions (HR
1.34, 95 % CI 1.01–1.78; P = 0.04) or a large tumor (HR
1.53, 95 % CI 1.17–2.00; P = 0.002) were independently
associated with higher risk of intrahepatic recurrence. In
addition, patients with mass-forming tumor ± periductal-
infiltrating morphology were more likely to develop
intrahepatic recurrence (HR 1.61, 95 % CI 1.00–2.60; P =
0.049). Extrahepatic recurrence was associated with sev-
eral factors, including micro- and macrovascular invasion,
R1 margin, perineural or biliary invasion, tumor grade,
periductal-infiltrating morphology, as well as lymph node
metastasis (all P \ 0.05; Table 2). After controlling for
competing risk factors, only the presence of lymph node
metastasis (HR 2.06, 95 % CI 1.30–3.26; P = 0.002) and
periductal-infiltrating morphology (HR 2.48, 95 % CI
1.13–5.45; P = 0.023) remained associated with an
increased risk of extrahepatic recurrence.
Treatment of Recurrence and Long-term Outcomes
Overall, 190 (47.5 %) patients received treatment for
recurrent ICC, whereas 210 (52.5 %) received BSC.
Among patients who received treatment for recurrent dis-
ease, therapy consisted of systemic chemotherapy only (n =
46, 24.2 %) or repeat liver-directed therapy ± systemic
chemotherapy (n = 144, 75.8 %). Repeat liver-directed
therapy consisted of repeat hepatic resection ± ablation
(n = 41, 28.5 %), ablation alone (n = 27, 18.7 %), or IAT (n =
76, 52.8 %; Supplementary Figure).
Older patients were more likely to undergo BSC (me-
dian age: 61.2 years, IQR 53.0–70.0) than liver-directed
therapy (median age: 55.5 years, IQR 45.8–65.6) or
chemotherapy only (median age: 57.3 years, IQR 49.0–
69.9; P = 0.001; Table 3). Patients who received repeat
liver-directed therapy were more likely to have a less
aggressive primary ICC, such as moderately differentiated,
stage I-II tumor, and no lymph node metastasis (all P\
0.05). Among patients with extrahepatic recurrence, the
most common treatment was systemic chemotherapy; in
contrast, patients with intrahepatic recurrence only were
more likely to receive repeat liver-directed therapy (P\
0.001). Interestingly, size and number of the recurrent
lesions did not correlate with different therapeutic
approaches (P\ 0.05).
Among patients who recurred, median survival from the
time of the recurrence was 11.1 months (BSC 8.0 months;
systemic chemotherapy only 16.8 months; liver-directed
therapy 18.0 months; P \ 0.001; Fig. 2). The median





































































FIG. 1 Five-year overall risk of recurrence stratified by site of
disease: intrahepatic (a), extrahepatic (b)
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TABLE 2 Univariable and multivariable cox proportional hazards models to predict (a) ‘‘any site’’ recurrence, (b) intrahepatic recurrence, and
(c) extrahepatic recurrence
Univariate Multivariate
HR (95 % CI) P value HR (95 % CI) P value
(a) ‘‘Any site’’ recurrence
Bilobar lesions 1.35 (1.09–1.67) 0.006 1.23 (0.98–1.55) 0.075
Cirrhosis 2.04 (1.38–3.01) 0.02 1.62 (1.17–2.25) 0.004
Multiple lesions 1.60 (1.29–1.97) \0.001 1.43 (1.15–1.78) 0.001
Size C7 cm 1.51 (1.23–1.84) \0.001 1.38 (1.11–1.70) 0.003
Vascular invasion
No vascular invasion Ref Ref
Microvascular invasion 1.75 (1.36–2.25) \0.001 1.56 (1.21–2.02) 0.001
Macrovascular invasion 1.88 (1.16–3.03) 0.01 1.41 (0.83–2.41) 0.206
Both micro- and macrovascular invasion 1.62 (1.12–2.36) 0.011 1.60 (1.06–2.42) 0.025
Direct invasion of contiguous organs 1.42 (1.03–1.97) 0.033 1.10 (0.74–1.63) 0.646
N stage
N0 Ref Ref
N1 1.56 (1.20–2.02) 0.001 1.46 (1.08–1.97) 0.012
T stage
T1-T2 Ref Ref
T3-T4 1.29 (1.01–1.66) 0.043 0.96 (0.71–1.30) 0.811
Histological grade
Well to moderately differentiated Ref Ref
Poorly to undifferentiated 1.40 (1.11–1.75) 0.004 1.30 (1.03–1.64) 0.024
Morphologic type
Mass-forming Ref Ref
Papillary 0.69 (0.42–1.15) 0.16 0.82 (0.49–1.38) 0.452
Periductal-infiltrating 1.56 (0.98–2.49) 0.059 1.70 (1.05–2.76) 0.032
Mass-forming ± periductal infiltrating 1.59 (1.10–2.28) 0.013 1.74 (1.16–2.63) 0.008
Adjuvant chemotherapy 1.03 (0.83–1.26) 0.809
Adjuvant radiotherapy 1.00 (0.72–1.38) 0.983
(b) Intrahepatic recurrence
Cirrhosis 1.77 (1.22–2.57) 0.003 1.91 (1.31–2.80) 0.001
Multiple lesions 1.43 (1.08–1.88) 0.012 1.34 (1.01–1.78) 0.04
Size C7 cm 1.55 (1.19–2.01) 0.001 1.53 (1.17–2.00) 0.002
Morphologic type
Mass-forming Ref Ref
Papillary 0.43 (0.19–0.98) 0.045 0.50 (0.22–1.15) 0.102
Periductal-infiltrating 0.99 (0.48–2.00) 0.97 0.90 (0.44–1.83) 0.771
Mass-forming ± periductal infiltrating 1.57 (0.98–2.53) 0.061 1.61 (1.00–2.60) 0.049
Adjuvant chemotherapy 0.94 (0.72–1.23) 0.643
Adjuvant radiotherapy 1.42 (0.90–2.26) 0.133
(c) Extrahepatic recurrence
Vascular invasion
No vascular invasion Ref Ref
Microvascular invasion 1.80 (1.22–2.65) 0.003 1.51 (0.99–2.30) 0.057
Macrovascular invasion 2.11 (1.02–4.35) 0.044 1.77 (0.84–3.76) 0.134
Both micro- and macrovascular invasion 1.94 (1.12–3.36) 0.018 1.47 (0.80–2.70) 0.212
R1 margin 1.56 (1.05–2.33) 0.028 1.19 (0.78–1.81) 0.429
Perineural invasion 1.80 (1.24–2.62) 0.002 1.30 (0.85–1.97) 0.224
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was 26.1 months versus 25.5 months for patients who
underwent ablation only and 9.6 months for patients who
had IAT (P = 0.01). More than half of patients (53.6 %)
who underwent a repeat resection ± ablation experienced a
second recurrence with a median time to second recurrence
of 11.5 months.
DISCUSSION
Intrahepatic cholangiocarcinoma is a rare, life-threat-
ening malignancy, which generally has a poor prognosis. In
fact, data from the current paper found that recurrence
following curative intent surgery for ICC was extremely
high. After surgery, less than one in five patients was alive
and free of disease 5 years following the date of surgery.
Given the high incidence of recurrent disease, under-
standing risk factors associated with recurrence and—
perhaps more importantly—the pattern, as well as man-
agement, of recurrent ICC disease is critical. The current
study is important, because—using a large, international,
multi-institutional cohort of patients—we defined the
incidence of recurrence to be 73.1 % at 5 years, as well as
characterized the overall pattern of ICC recurrence fol-
lowing curative intent surgery. More than half of patients
developed recurrence within 1 year, and the median RFS
was only 11.2 months. Of note, the most common pattern
of recurrence was intrahepatic (59.8 %), whereas fewer
patients had an extrahepatic component of recurrent dis-
ease (40.2 %). Although ICC most often recurred in the
liver, only half of patients were suitable for treatment at the
time of recurrence. Interestingly, among those patients who
underwent repeat liver-directed therapy, outcomes were
poor with more than half of patients experiencing a second
recurrence within 12 months following repeat resection.
Despite the curative-intent of surgery, recurrence was
common following surgical resection; only 17.4 % of
patients were recurrence-free at 5 years. In fact, with a
median follow-up of 19 months, 71.0 % of patients had
developed either an intra- or extrahepatic recurrence. These
data corroborate previous reports that have similarly noted
the aggressive natural history of ICC.5,10–15 Although the
most common recurrence site was the liver, recurrence
outside of the liver also was common (Table 1). Interest-
ingly, median and 5-year RFS were comparable among
patients who presented with either intra- or extrahepatic
disease as the first site of their recurrence. We noted that
factors, such as cirrhosis of the background liver, as well as
specific morphological features, such as periductal-infil-
trating tumor or mass-forming tumor ± periductal-
infiltrating morphology, were independent predictors of
‘‘any site’’ recurrence. Certain tumor-level factors also
were associated with specific patterns of recurrence. For
example, multifocal ICC and large tumor size were inde-
pendent predictors of intrahepatic recurrence, whereas the
presence of lymph node metastasis substantially increased
the risk of extrahepatic disease. Data from our group and
others have emphasized the importance of assessing the
lymph node basin to stage patients accurately.9,25–27 The
finding that lymph node metastasis were strongly associ-
ated with risk of extrahepatic recurrence serves to
emphasize the importance of assessing the regional nodal
basins. While lymph node metastasis may indeed portend a
TABLE 2 continued
Univariate Multivariate
HR (95 % CI) P value HR (95 % CI) P value
Biliary invasion 1.72 (1.15–2.58) 0.008 1.26 (0.81–1.97) 0.3
N stage
N0 Ref Ref
N1 1.95 (1.31–2.89) 0.001 2.06 (1.30–3.26) 0.002
Histological grade
Well to moderately differentiated Ref Ref
Poorly to undifferentiated 1.53 (1.07–2.19) 0.02 1.39 (0.96–2.01) 0.077
Morphologic type
Mass-forming Ref Ref
Papillary 1.48 (0.74–2.95) 0.262 1.47 (0.72–3.00) 0.294
Periductal-infiltrating 2.46 (1.24–4.90) 0.01 2.48 (1.13–5.45) 0.023
Mass-forming ± periductal infiltrating 1.31 (0.66–2.60) 0.446 1.17 (0.55–2.48) 0.674
Adjuvant chemotherapy 1.05 (0.75–1.47) 0.767
Adjuvant radiotherapy 0.65 (0.41–1.03) 0.064
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higher risk of extrahepatic recurrence and indicate the need
for adjuvant therapy, postoperative therapy unfortunately
remains largely ineffective. For example, in the current
study, use of adjuvant treatment, including chemotherapy
and/or radiotherapy, was not protective from ‘‘any site’’
recurrence or site-specific recurrence (Table 2). These data
support previous reports noting the marginal beneficial
effect of adjuvant therapy on the long-term oncological
outcome of patients with resected ICC.8,9
While repeat hepatectomy has been advocated as the
treatment of choice for recurrent colorectal liver metastasis
and some patients with recurrent hepatocellular carcinoma,
few studies have specifically explored different manage-
ment options for patients with recurrent ICC.16,17
Interestingly, only half of patients with recurrent disease
were considered suitable for treatment, such as systemic
chemotherapy or liver-directed therapy, while the remain-
ing patients were managed with BSC only (Supplementary
Figure). Perhaps not surprisingly, older patients and those
with advanced disease were more likely to receive BSC,
whereas patients who had a history of a less aggressive
primary tumor (e.g., earlier stage, no nodal metastasis,
lower tumor stage) and intrahepatic only recurrence more
often underwent repeat liver-directed therapy. Repeat liver-
directed therapy most often consisted of IAT, followed by
resection ± ablation and ablation only (Supplementary
Figure). IAT has been previously described as a potentially
effective therapy for patients with primary, unresectable
ICC. Hyder et al. reported 198 patients with advanced ICC
treated with IAT and reported a median overall survival of
13.2 months.28 In the current study, the use of IAT for
recurrent ICC was associated with a comparable—albeit
TABLE 3 Patient and tumor factors and recurrence patterns stratified by treatment of recurrence among patients with curative-intent therapy for
intrahepatic cholangiocarcinoma
Best supportive care (n = 210) Liver-directed therapy (n = 144) Chemotherapy-only (n = 46) P
Age 61.2 (53.0–70.0) 55.5 (45.8–65.5) 57.3 (49.0–69.9) 0.001
Sex (n = 399) 0.005
Male 108 (51.7) 89 (61.8) 16 (34.8)
Female 101 (48.3) 55 (38.2) 30 (65.2)
Cirrhosis 14 (6.7) 30 (20.8) 3 (6.5) \0.001
Nodal status \0.001
Positive 47 (22.4) 19 (13.2) 8 (17.4)
Negative 63 (30.0) 87 (60.4) 25 (54.3)
Not harvested 100 (47.6) 38 (26.4) 13 (28.3)
AJCC T stage (n = 382) 0.507
T1 69 (34.3) 59 (43.4) 22 (48.9)
T2 85 (42.3) 53 (39.0) 15 (33.3)
T3 31 (15.4) 15 (11.0) 5 (11.1)
T4 16 (8.0) 9 (6.6) 3 (6.7)
AJCC (n = 250) 0.002
I 25 (22.5) 43 (40.6) 13 (39.4)
II 29 (26.1) 34 (32.1) 8 (24.2)
III 3 (2.7) 6 (5.7) 3 (9.1)
IVa 54 (48.6) 23 (21.7) 9 (27.3)
Tumor grade (n = 391) 0.149
Well 28 (13.5) 10 (7.1) 5 (11.9)
Moderate 117 (56.2) 96 (68.1) 28 (66.7)
Poor or undifferentiated 63 (30.3) 35 (24.8) 9 (21.4)
R0 margin 163 (78.4) 126 (87.5) 39 (84.8) 0.272
Recurrence site \0.001
Intrahepatic only 109 (51.9) 117 (81.2) 13 (28.3)
Extrahepatic only 39 (18.6) 3 (2.1) 16 (34.8)
Intrahepatic ? extrahepatic 62 (29.5) 24 (16.7) 17 (37.0)
Size of recurrent tumor NA 4 (2.4–8.1) 3.0 (2.4–3.7) 0.450
Number of recurrent lesions 2 (2–2) 1 (1–2) 1 (1-2) 0.950
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somewhat shorter—survival of just under 10 months. In
contrast, the survival of patients undergoing resection or
ablation was longer at 25-26 months. While this was con-
siderably longer than IAT or BSC, it is important to note
that the benefit of resection was not particularly durable.
Collectively, the data strongly suggest that while repeat
resection may be considered for a select subgroup of
patients with recurrent intrahepatic ICC, the benefits of
surgery are modest.
The current study had several limitations. Due to the
retrospective nature, there may be selection/detection bia-
ses in our ascertainment of the pattern of recurrence.
Although all the participating surgical departments queried
institution-wide databases for information on recurrence
and treatment, due to the surgical nature of the collabora-
tion and of the dataset, recurrence may be underreported.
However, these data should be missing at random and not
affect the underlying findings of the current study. In
addition, because this study was a multi-institutional col-
laboration among 12 academic institutions, operative and
follow-up treatment protocols were not rigorously stan-
dardized. However, using a multi-institutional study cohort
also was a major strength, because it conferred a larger
sample size and more generalizable results. Another limi-
tation of the study was that we included patients who
underwent surgery for ICC in a large time period, between
1990 and 2013. This could have led to differences in
diagnostic, therapeutical, and follow-up protocols in the
same institution and between the different institutions.
CONCLUSIONS
Recurrence following curative-intent resection of ICC is
common, occurring in up to two-thirds of patients within
approximately 12 months of surgery. Intrahepatic recur-
rence was the most common pattern of initial recurrence,
although extrahepatic recurrence also was frequent. The
most common treatment of recurrent disease was BSC,
while IAT was the most common liver-directed treatment.
Only 9 % of all patients underwent repeated liver resection
when there was a recurrence. Resection was associated
with only a modest survival benefit, because most patients
developed a second recurrence within 12 months.
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